SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery

Autor: Harry L. Malech, Roberta E. Parrott, Evan Shereck, Kenneth B. DeSantes, Troy C. Quigg, Thomas A. Fleisher, Alfred P. Gillio, Rebecca H. Buckley, Richard J. O'Reilly, Sung-Yun Pai, Luigi D. Notarangelo, Victor M. Aquino, Morton J. Cowan, Jeffrey J. Bednarski, Jennifer M. Puck, Donald B. Kohn, David C. Shyr, Soma Jyonouchi, Imelda C. Hanson, Pierre Teira, Matthew H. Porteus, Angela R. Smith, Paul Szabolcs, Candace Taylor, Jeffrey H. Davis, Mark Vander Lugt, Jack J. Bleesing, Morris Kletzel, Hélène Decaluwe, Megan Murnane, Christine M. Seroogy, Trudy N. Small, James A. Connelly, Audrey G. Tumlin, Sharat Chandra, Matthew E. Cavanaugh, Kathleen E. Sullivan, Ann E. Haight, Aleksandra Petrovic, Linda M. Griffith, Neena Kapoor, Brent R. Logan, John Craddock, Susan E. Prockop, Michael A. Pulsipher, Michael D. Keller, Geoffrey D.E. Cuvelier, Caridad Martinez, Jessica Chaisson, Frederick D. Goldman, Alan P. Knutsen, Monica S. Thakar, Lolie C. Yu, Ziyan Yin, Lauri Burroughs, William T. Shearer, Hisham Abdel-Azim, Jennifer W. Leiding, Jennifer Heimall, Elie Haddad, Christopher C. Dvorak, Theodore B. Moore, Blachy J. Dávila Saldaña, Elizabeth M. Kang, Suzanne Skoda-Smith

Publikováno v: Blood. 132:1737-1749

The Primary Immune Deficiency Treatment Consortium (PIDTC) performed a retrospective analysis of 662 patients with severe combined immunodeficiency (SCID) who received a hematopoietic cell transplantation (HCT) as first-line treatment between 1982 an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77d6ef98c53eabc748b1041f481c507e
https://doi.org/10.1182/blood-2018-03-840702